Peptide Blend COA Limits: Why One Purity Number Cannot Certify a Two-Component Vial

A peptide blend COA cannot be reduced to a single purity percentage, because a vial holding two declared peptides has no one main peak for that percentage to describe. Certifying a co-formulated vial requires a separate content assay for each component, verification of the ratio between them, and orthogonal identity confirmation for both. A certificate reporting one purity figure and one identity for a two-peptide product has not characterised the product it claims to describe.

Blended research peptide vials have become routine in the Canadian and international grey market. Combinations pairing a growth hormone releasing hormone analogue with a growth hormone secretagogue, or a cytoprotective pentadecapeptide with an actin sequestering polypeptide, are sold as single lyophilised units carrying a single certificate. The analytical literature that underpins peptide quality control was built almost entirely around single active substances, and the reporting conventions inherited from that literature break in specific, predictable ways when a second declared active is introduced into the same vial. Understanding exactly where they break is the difference between a certificate that documents a product and a certificate that decorates it.

Why Area Percent Purity Has No Meaning in a Two-Component Vial

Reversed-phase HPLC purity is conventionally expressed as area percent: the integrated area of the target peak divided by the total integrated area of everything the detector registered, multiplied by one hundred. The arithmetic is normalised, which means the result always sums to one hundred percent across the chromatogram regardless of what is actually in the vial. In a single-active preparation this convention is serviceable. The target peptide is the main peak, everything else is an impurity, and the ratio between them carries real information about synthesis and purification quality.

In a deliberately co-formulated vial the same arithmetic produces nonsense. The second declared active is not an impurity, but area normalisation has no way to know that. A vial containing roughly equal quantities of two peptides with comparable ultraviolet absorbance would return something near fifty percent area for each peak. Reported as purity, that figure describes a catastrophic quality failure. Reported honestly, it describes a product that contains precisely what its label declares. The number is not wrong so much as it is answering a question nobody asked.

The common workaround is to publish the purity of each peptide as measured on the separate single-component batches used as blending inputs. This is more defensible than a meaningless combined figure, but it certifies the wrong object. Input purity describes material that existed prior to blending. It carries no information about whether the blending operation transferred the correct quantities, whether the components were homogeneously mixed before filling, or whether either component degraded during the additional handling that blending necessarily introduces. A certificate built exclusively on pre-blend data is a certificate for a product that no longer exists in that form.

Assay and Purity Answer Different Questions

Purity is a ratio and carries no units. Assay, more precisely termed content, is an absolute quantity determined against a characterised reference standard, and it is the measurement that actually answers whether the declared amount of each peptide is present in the vial. The distinction matters for single-component products, where a vial can be ninety-nine percent pure and still contain substantially less material than the label states. It matters far more for blends, because a blend has two content values and one relationship between them, and all three can fail independently.

Content determination depends on the availability and quality of a reference standard for each component, which is where blend certification runs into a structural problem. Well characterised reference standards exist for compounds with pharmacopoeial monographs. Most compounds appearing in research blends have no monograph and no certified reference material, so laboratories rely on in-house standards whose own assignment is uncertain. This is the mechanism behind documented interlaboratory disagreement on peptide content, examined in our analysis of peptide reference standards and why laboratories disagree on purity. A blend inherits that uncertainty twice over, once for each declared component.

Key Research Findings

• Vanhee et al., Talanta, 2015, volume 142, pages 1-10, presented an LC-MS/MS screening method resolving 25 different peptides in a single 30 minute run, incorporating the recommended minimum of five identification points for confirmatory analysis.
• The paired UHPLC-DAD quantification method in that study was validated for a representative subset of 10 peptides using the total error approach, in accordance with ISO 17025 validation requirements, and achieved quantification without derivatisation or isotopically labelled peptide standards.
• Janvier et al., Talanta, 2018, volume 188, pages 795-807, conducted a systematic screening of the ten most frequently encountered falsified peptide drugs on the Belgian market, acquired from three separate suspected illegal internet pharmacies, and reported high variation in the amount of drug present per unit.
• That study measured purities ranging between 5 percent and 75 percent for cysteine containing peptides, the widest documented purity spread in the falsified peptide literature.
• Multiple samples in the same study carried arsenic or lead at concentrations up to ten times the ICH toxicity limit for parenteral products, and arsenic speciation confirmed that all arsenic detected was present in the more toxic inorganic form.
• The ten compounds examined were epitalon, GHRP-2, GHRP-6, ipamorelin, oxytocin, melanotan II, thymosin beta-4, AOD-9604, sermorelin and CJC-1295, which are the same compound families that appear in commercially blended research vials.

What the Falsified Peptide Literature Shows About Content Control

The Janvier work is the most systematic published characterisation of grey market peptide quality, and its central finding is not the heavy metal contamination that tends to get quoted. It is the variation in amount of material per unit across samples that were nominally the same product. Purity and content decoupled completely: preparations could carry acceptable chromatographic purity while holding an arbitrary quantity of peptide, because nothing in the supply chain was controlling fill accuracy or verifying content against a standard.

That finding transfers directly to blends, and worsens. If fill and content control are unreliable for a single-component vial, a blended vial adds a mixing operation, a second weighing operation, and a second reference standard, each with its own error. The Vanhee methodology demonstrates that simultaneous identification and quantification of multiple peptides in one preparation is analytically achievable, since a single validated run resolved 25 distinct peptides with confirmatory identification points. The capability exists. The question a purchaser should ask is whether a given supplier has actually applied it to the blended product, or has simply attached two single-component certificates to a mixed vial.

Ratio Integrity Is a Separate Failure Mode

A blend can fail in a way that no single-component product can: total peptide content can be correct while the proportion between components is wrong. A vial declaring five milligrams of each of two peptides and actually containing eight and two would assay correctly for total peptide mass. Only a component-resolved assay detects it, and only if the certificate reports each component separately rather than a combined total.

Co-elution Becomes More Likely by Design

Peptides are frequently blended because they are used together, and compounds used together are often structurally and physicochemically similar. Similar hydrophobicity means similar retention on a C18 column. Two declared actives emerging at nearly the same retention time integrate as one peak, and a method that has not been specifically developed to resolve that pair will report a single merged area that cannot be apportioned. This is the same analytical blind spot examined in our work on peptide cross-contamination and the impurity a purity number cannot see, with one important difference. Cross-contamination is accidental and unknown to the manufacturer. Blend co-elution is foreseeable from the formulation itself, which means a supplier has no excuse for not having developed a method that separates the pair before releasing the product.

Differential Degradation Moves the Ratio During Storage

Two peptides in one vial do not age at the same rate. Degradation chemistry is sequence specific: methionine containing peptides are susceptible to oxidation, asparagine and glutamine residues drive deamidation, cysteine containing sequences are vulnerable to disulfide scrambling, and N-terminal sequences of particular composition can undergo diketopiperazine formation. A blend pairing a stable pentapeptide with a longer oxidation-prone sequence will drift in ratio over its shelf life even under correct storage, because one component is disappearing faster than the other.

The consequence is that blend stability cannot be inferred by consulting the stability data of each component separately. The pair must be studied as the pair, in the actual formulation, because excipients, residual moisture and pH interact with both sequences simultaneously. Very few research blend products are supported by stability data generated on the blend itself.

How Regulated Fixed Ratio Peptide Products Are Controlled

Fixed ratio peptide co-formulations do exist under full regulatory oversight, and the contrast is instructive. The insulin degludec and liraglutide co-formulation marketed as Xultophy is specified as a fixed ratio product declaring 100 units of insulin degludec and 3.6 milligrams of liraglutide per millilitre, a composition approved by both the European Medicines Agency and the United States Food and Drug Administration. The ratio itself is a registered specification, not an incidental property of the manufacturing run.

Bringing that product to market required analytical methods capable of resolving and quantifying both actives in the presence of one another, stability data generated on the co-formulation rather than on its inputs, and content uniformity controls demonstrating that the declared ratio holds across units. That is the standard a fixed ratio peptide product is held to when a regulator is watching. Research blends sold with a single inherited purity figure are not approaching it, and the gap is not a technical impossibility. It is a choice about what to test and what to publish.

What a Defensible Blend Certificate Contains

A certificate that genuinely characterises a two-component vial reports identity for each declared peptide by mass spectrometry, with observed and theoretical monoisotopic masses stated separately for both. It reports chromatographic purity for each component individually, measured on a method demonstrated to resolve the two actives, with the resolution figure disclosed. It reports content for each component against a named reference standard, expressed as an absolute quantity, so that the declared ratio can be checked arithmetically rather than assumed. It states the analytical method and the laboratory, and it is tied to the specific blended lot rather than to the single-component lots used as inputs.

It should also state what was not tested, since sampling governs how far any of those numbers generalise from the tested unit to the vial in hand, a limitation examined in our discussion of vial content uniformity and batch sampling. Researchers evaluating co-formulated products such as a CJC-1295 and ipamorelin blend should apply these criteria to whatever documentation is supplied, and can review the batch-specific documents published on our certificates of analysis page against them.

Limitations and Open Questions

The evidence base here is thinner than the analytical case deserves. The Janvier and Vanhee studies characterise single-component falsified preparations, and no equivalent systematic survey of multi-component research blends has been published. The inference that blending compounds existing content control failures is well grounded in manufacturing logic but has not been measured directly, and that gap should be stated plainly rather than papered over.

There is also no pharmacopoeial monograph for any of the peptide combinations circulating in the research market, which means there is no external specification against which a supplier’s blend method can be judged. Until reference standards and monographs exist for these compounds, component-resolved certification depends entirely on the rigour of the individual testing laboratory and on the willingness of a supplier to pay for a harder analysis than the market currently demands.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.